I don't really have anything to comment on specifically to the last point, but there was the concern that was earlier addressed that somehow the PMPRB was going to supplant the government drug program negotiations. Of course that's not the case. We're setting a ceiling and they can negotiate below that ceiling, but we have to remember that 57% of the market is not even part of those government-planned negotiations. We're there to protect against excessive pricing, especially in the 57% who don't have a common voice negotiating on their behalf.
On November 23rd, 2020. See this statement in context.